Autologous peripheral blood progenitor cell (PBPC) transplantation frequently requires sequential placement and use of two separate central venous catheters: (1) a short-term, large-bore, stiff device inserted for leukapheresis, and after removal of that device, (2) a longterm, multi-lumen, flexible, Silastic catheter for administration of high-dose chemotherapy, re-infusion of hematopoietic cells, and intensive supportive care. We reviewed our recent experience with two dual-lumen, large-bore, Silastic multi-purpose ('hybrid') catheters, each of which can be used as a single device for both leukapheresis and long-term supportive care throughout the transplant process. Quinton-Raaf PermCath and Bard-Hickman hemodialysis/apheresis dual-lumen catheters were used as the sole venous access device in 112 consecutive patients who underwent autologous PBPC collection and transplantation. The catheter exit site was monitored three times a week, and lumen patency was assessed using clinical and radiologic techniques. Catheters were removed prematurely for persistent thrombus, positive blood cultures despite appropriate antibiotics, or mechanical dysfunction. There were no intra-operative or immediate post-operative complications relating to insertion. Thirty-two patients experienced catheter occlusion necessitating urokinase instillation. Persistent occlusive problems were noted in 16 patients, and in 10 patients the catheter had to be removed. Two exit site infections and 17 bacteremias occurred. Catheters had to be removed for persistent infection in two subjects and for mechanical problems in five others. Cost analysis comparing the hybrid catheters alone vs conventional devices revealed a charge of $4230 in patients with hybrid catheters vs $7530 in those requiring a temporary non-Silastic dialysis catheter in addition to a flexible, long-term Silastic catheter. Hybrid, Silastic, dual-lumen, large-bore central venous catheters are safe, cost-effective and convenient multi-purpose venous access devices that may be used in the setting of autologous PBPC collection and transplantation. 
Hematopoietic progenitor cell transplantation is an effective treatment for a variety of malignant and non-malignant diseases. 1, 2 In recent years, the use of peripheral blood progenitor cells (PBPC) has nearly supplanted bone marrow as the preferred autologous hematopoietic progenitor cell source for reconstitution after myeloablative chemotherapy. This strategy is due, in part, to enhanced recovery of peripheral blood cell counts, fewer infections during transplant, lower early transplant-related mortality, and shorter duration of hospital stay. [3] [4] [5] [6] [7] [8] In the past, PBPC were usually collected via a largebore, stiff, non-Silastic dual-lumen central venous catheter by continuous flow cell processors during consecutive apheresis sessions, after mobilization by priming with cytokines, chemotherapeutic agents, or a combination. The apheresis procedure is lengthy and time-consuming, since large blood volumes must be processed during multiple leukapheresis procedures to obtain an adequate number of circulating progenitor cells. [9] [10] [11] The sterile integrity of the apheresis catheter and product must be maintained throughout the period of leukapheresis, cryopreservation, thawing, and reinfusion. [12] [13] [14] On the other hand, the transplant process typically involves the use of a long-term, Silastic, multilumen, smaller-bore, flexible catheter for chemotherapy administration, infusion of hematopoietic cells and supportive care management including frequent blood sampling, intravenous antibiotics, analgesics, anti-emetics, blood components and parenteral nutrition. Since different catheter properties are required, the transplant procedure traditionally involved insertion of two venous access devices, one for collection of PBPC and another for chemotherapy administration, progenitor cell infusion, and supportive care both during and after the transplant.
The Bard-Hickman hemodialysis/apheresis round duallumen catheter and the Quinton-Raaf PermCath (first described as the Quinton HemoCath 15 ) catheters are relatively new, multi-purpose, large-bore, multi-lumen, Silastic, long-term central venous catheters that may be used for both leukapheresis and the intensive long-term support of the transplant patient. 15, 16 We reviewed our experience using these hybrid catheters in 112 consecutive patients undergoing autologous peripheral blood progenitor cell transplantation and noted this device to be an effective adjunct in this setting. [17] [18] [19] [20] PBPC were collected using the double-lumen Quinton-Raaf PermCath (Quinton, Seattle, WA, USA) or the Bard-Hickman hemodialysis/aphereses 13.5F round dual-lumen catheter (Bard, Salt Lake City, UT, USA) ( Figure 1 ) in conjunction with the COBE Spectra pheresis instrument (COBE, Lakewood, CO, USA). In those patients in whom high-dose cytotoxic therapy and autotransplants were performed subsequently, treatment was administered according to protocols approved by our Institutional Review Board for Human Investigation.
Patients and methods

At
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Hybrid catheter insertion technique
In most instances, catheter placement was undertaken at the initiation of mobilization therapy. Double-lumen devices 36 cm or 40 cm in length were inserted by one of 13 staff surgeons. Bard-Hickman catheters (13.5 French, round) were placed into the subclavian vein using a closed peelaway sheath technique (n = 85), and the final desired location of the tip was the superior vena cava. 26 The Quinton-Raaf PermCath device (oval) (n = 27) was inserted using an open cut-down approach into the internal jugular vein, and the final desired location of the tip (confirmed by fluoroscopy) was the right atrium. 16, 27, 28 The difference in configurations between the two catheters is shown in Figure  2 . The PermCath has two round lumens and an outer oval shape, whereas the Bard-Hickman has D-shaped lumens (together, a double-D shape) and a round outer configuration. All catheters were tunneled subcutaneously with the Dacron cuff positioned in mid tunnel. Prophylactic antibacterial agents were not given routinely at the time of catheter insertion. Surgeons obtained a chest radiograph after percutaneous insertion to confirm the correct position and to detect the presence of an asymptomatic pneumothorax. In one patient the catheter was inserted into the femoral vein, due to thrombosis of the large upper body veins. 29 
Catheter care
The exit site was kept dry and was either cleaned at least three times a week using aqueous-based povidone iodine (Professional Disposables, Mt Vernon, NY, USA) and covered with an occlusive dressing that permitted access to the catheter extensions, or maintained using a Biopatch (Johnson & Johnson Medical, Arlington, TX, USA) changed weekly. To maintain patency between treatments, the lumina of the catheter were primed with 2 ml of sodium heparin 1000 units/ml (Elkins-Sinn, Cherry Hill, NJ, USA). Oral anticoagulants such as coumadin or aspirin were not given routinely.
Monitoring and addressing complications
It was intended that all catheters would remain in place throughout the PBPC mobilization and collection procedures, as well as during the transplant and immediate post-transplant period, ie until transfusion independence, completion of parenteral antibiotic therapy, and completion of electrolyte replacement therapy were achieved. Interventions were undertaken when the patient or professional staff noted difficulty with either infusing fluids or withdrawing blood. The initial approach was to instill 2 ml of urokinase (Abbott, North Chicago, IL, USA) 5000 units/ml into each lumen for 45 min, and then withdraw the antico- agulant. If this maneuver did not correct the problem, a venogram or ultrasound of the catheter tip was performed. For clots noted at the catheter tip, an infusion of urokinase (500 units/kg patient weight/h) was begun through the catheter. Approximately 24-36 h after beginning the infusion, the venogram or ultrasound was repeated. If the clot did not lyse, the catheter was removed (see below). For erythema, induration, tenderness or discharge at the catheter exit site, blood cultures were obtained from both a peripheral vein and both catheter lumina. Appropriate antibacterials were instituted for positive cultures. If the blood cultures remained positive for 48 h despite initiating therapy, or the erythema, induration, or tenderness progressed despite appropriate therapy, the catheter was removed and the tip cultured for microorganisms.
Catheter repair and removal
Catheters were repaired at the bedside for mechanical problems such as breakage or leakage using the kit provided by the manufacturer (Bard Access System and Quinton). Catheters were removed as described previously either in the operating room or at the bedside by the same surgeons. 30 Catheters were removed at the completion of all therapy ('completion'), for persistent infection or thrombus despite appropriate therapy, for continued difficulty during infusing or withdrawing fluid in the absence of obvious infection or clot, severe local pain, and mechanical failure, ie fracture.
Cost analysis
We performed a cost analysis in order to evaluate whether a single, multipurpose catheter would be more cost-effective than having two catheters. Charges for appliances, facilities, and personnel during the 1995-1998 study period were obtained and means were calculated. We compared total mean charges for all aspects of insertion of a hybrid Silastic catheter vs a combination of a temporary dialysis catheter and a conventional Silastic catheter such as a Hickman or Broviac catheter (Bard) in patients undergoing highdose chemotherapy and peripheral blood hematopoietic cell transplantation.
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Results
Insertion
A total of 112 patients, median age 46 years (range 17-70 years) considered for high-dose chemotherapy and hematopoietic cell transplantation received either a Bard-Hickman (n = 85) or PermCath (n = 27) central venous hybrid catheter (Table 1) . Catheters were usually inserted at the time chemotherapy was initiated for mobilization of hematopoietic stem cells. Of these, 40 catheters were inserted into the internal jugular vein and 71 into the subclavian vein. In one patient, anatomical problems precluded placement in the neck and chest region; a catheter was inserted into the femoral vein according to previously published techniques. 29 The catheters remained in place for a median dur- 
Complications during insertion
Chest radiographs obtained after insertion revealed there were no pneumothoraces. Eighteen patients required more than one attempt at cannulating the vein when the percutaneous method was used, while the device was inserted percutaneously on the first pass in 94 subjects (Table 2) . One patient had local bleeding which developed 6 h after the procedure and was controlled easily without surgical intervention.
Mobilization of hematopoietic stem cells
Twelve patients received hematopoietic growth factors G-CSF, GM-CSF, or a combination. Alternatively, 94 patients were given chemotherapy regimens plus G-CSF. Six patients underwent hematopoietic stem cell collection after chemotherapy alone. The catheters were used to undertake Table 2) . No fungemias were noted.
Thrombotic and mechanical problems
Thirty-two patients experienced difficulties during infusion of intravenous fluids or during withdrawal of blood; in 16 subjects a single urokinase instillation or infusion eradicated the problem. Persistent problems were noted, however, in 16 patients, in whom further diagnostic studies and repeated urokinase infusions were required. Venograms revealed thrombi (n = 10) at the catheter tip and fibrin sheaths (n = 2) which resolved with additional fibrinolysis therapy. In 10 patients catheter-related intra-luminal or extra-luminal thrombosis necessitated removal of the device ( Table 2 ). The catheter was removed in five subjects for (one each): leakage around the exit site thought to have been caused by a cutaneous suture needle, severe upper extremity pain possibly due to brachial plexus nerve compression, accidental removal (by a patient at home), persistent upper extremity swelling, and spontaneous catheter fracture during routine flushing (Table 2 ). In the latter instance, the catheter tip embolized to the right atrium, and the patient underwent a cardiac catheterization to retrieve the device. Table 3 shows the approximate charges for insertion of the multi-purpose dual-lumen catheters vs both a non-Silastic pheresis and a conventional Silastic central venous catheter. An anticipated savings of approximately $3000 per patient can be realized, in part due to the use of one rather than two uses of the operating room. Such charges, however, could vary greatly if catheter insertion was undertaken by interventional radiology personnel (without the need for an operating room), or performed 'blind', ie without the use of real-time imaging.
Costs
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Dicussion
Central venous catheters represent a major advance in the management of cancer patients, especially in those subjects undergoing hematopoietic cell transplantation. 34 Use of these devices, however, often is associated with infection and thrombosis, even in the severely thrombocytopenic patient. Such drawbacks have been reported with use of long-term, tunneled catheters 28, 29, [31] [32] [33] [34] [35] during the immediate pre-transplant, transplant, and post-transplant periods. Similarly, difficulties often are observed during the usually shorter period of leukapheresis. [36] [37] [38] [39] [40] [41] PBPC collection requires the use of high-flow catheter for adequate cell collection through apheresis, and supportive care needs may be extensive. 42 To execute the subsequent transplant, in addition, requires a conventional central venous catheter. Hence, these requirements usually are achieved by insertion of two separate catheters. We were concerned that use of a larger bore, stiffer catheter in severely pancytopenic patients might be associated with increased complications. Our experience with the new hybrid Silastic, dual-lumen catheters suggests that they can be inserted safely. Most patients in our series underwent insertion during the first attempt, and no peri-operative complications were noted. Patients underwent 399 leukapheresis procedures, and median time with catheter in situ was 63 days (range 7 to 190 days). Catheters usually were left in place until frequent platelet transfusions and parenteral electrolyte replacement no longer were required after transplant.
Only two bacteremias developed during the pheresis period, despite neutropenia during the chemotherapy mobilization period. Only two local exit site infections (2%) and 15 bacteremias (13%) were noted during the period of transplantation. In our study all but three patients with bacteremia could be treated successfully using antibiotics without removal of the device. Although most patients received prophylactic oral antibiotics during the pheresis period, no prophylactic antibiotics were given during the transplant period. Despite the large catheter size, these results are similar to published reports in hematopoietic stem cell transplant patients with central venous catheters used for pheresis, transplant, or both (Table 4) . [38] [39] [40] 42, [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] For patients treated using conventional chemotherapy regimens in which catheter duration extended from 1 to 1715 days, bacteremias ranged from 5 to 22%. [43] [44] [45] [46] [47] [48] For six series disseminated infection experiences during pheresis (with or without hematopoietic stem cell transplantation) ranged from 2 to 9%. [38] [39] [40] [49] [50] [51] Many of the reports for the above two situations, however, failed to provide essential details such as in situ duration of catheters and number of local and blood-borne infections. Finally, for six large reports in which central venous catheters were used for 1-533 days during transplantation, bloodstream infections ranged from 4 to 39%. 42, [52] [53] [54] [55] [56] In our study and in the published literature, the majority of the organisms recovered were skin commensals. Recent studies have reported reduction of infection in patients undergoing conventional chemotherapy with non-tunneled antiseptic-impregnated or antibiotic-coated catheters. [57] [58] [59] This approach reduces micro-organism colonization and subsequent infectious complications. Future devices may address this option for hybrid, large-bore, Silastic, duallumen catheters.
Nearly one-third of our patients (32 of 112, 29%), however, experienced problems with either infusing or withdrawing blood and fluids. This dilemma, often due to thrombi or fibrin sheaths, was persistent in 16 patients but Bone Marrow Transplantation resolved with urokinase therapy. Our favorable experience resolving this problem is in contrast to that of Horne et al 60 who reported that the addition of heparin to urokinase infusions did not improve resolution of catheter-tip fibrin sheaths in 42 patients. It was necessary to remove the device in 10 patients because the catheter-related thrombosis persisted. Other studies have noted an extremely diverse incidence for catheter dysfunction, especially thrombosis, as a significant problem (Table 4) . We did not observe more serious problems such as pneumothorax or hemothorax.
We report that despite severe thrombocytopenia, thrombosis represents a more difficult management problem than infection and resulted in premature removal of more catheters. Goldberg et al 39 reported significant catheter dysfunction from catheter occlusions with Davol or Vascath devices in 38 of 75 patients undergoing pheresis prior to autotransplant. Haire and associates 53 also reported a high complication rate, including thrombosis in 10 of 23 patients undergoing transplant using a Hickman or Groshong cath-eter. Fibrin sheaths appear to develop at a high rate, and use of anti-fibrinolytic therapy poses a significant risk in this patient population.
Our large-bore, dual-lumen catheter experience is one of the first reports describing the use of Silastic catheters as multi-purpose devices in the hematopoietic cell transplant setting. These hybrid devices may be left in place indefinitely for pheresis and venous access during the transplant procedure. Because of the cost savings, relatively low complication rate, and convenience, these instruments should be considered in the future for venous access in this group of patients.
